AVN trial delaysWhy recruiting for the AVN trial did not begin in early 2023 is puzzling. The reason was that the Ethics Committee had to approve the study which IMHO sounds routine. AVN has a well known safety profile. I'm sure the BG pill study had to go through the Ethics Committee especially given that some patients wanted BG as a stand alone therapy. Whatever the process is, it should have been accounted for when the statement was made that recruiting for the study would begin in early 2023.
Given Ronnie's prior history with MHI when he was in Roche, where is his influence if needed to expedite a routine review?
https://www.icm-mhi.org/en/montreal-heart-institute-becomes-roche-global-research-hub-cardiometabolic-disease